BillionToOne Soars: 113% Q4 Revenue Growth, Profitability Achieved, 2026 Guidance Raised
summarizeSummary
BillionToOne reported exceptionally strong fourth quarter and full year 2025 results, highlighted by a 113% year-over-year increase in Q4 revenue to $96.1 million. The company achieved significant gross margin expansion to 71% and transitioned from an operating loss to a $10.3 million operating profit in Q4 2025, alongside positive cash flow. Management also raised its full-year 2026 revenue guidance to a range of $430 million to $445 million, representing 41% to 46% growth over 2025, and anticipates positive operating income for the full year. These results underscore robust demand for their prenatal and oncology diagnostic tests, with oncology revenue growing over 8x in Q4. The strong financial performance and optimistic outlook, coupled with recent product launches, suggest continued momentum and validate the company's growth strategy. Traders will be watching for sustained execution against the elevated 2026 targets and further expansion of their diagnostic platform.
At the time of this announcement, BLLN was trading at $80.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $66.00 to $138.70. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.